Peptide comparison
Both are GHRH analogs that stimulate the pituitary through the same receptor. The difference is not the pathway but how long they last: it is a textbook case of how half-life engineering changes a peptide's behavior.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| Sermorelin | CJC-1295 | |
|---|---|---|
| Class | GHRH analog — GHRH(1-29) fragment | Long-acting GHRH analog |
| Receptor | GHRH receptor | GHRH receptor |
| Duration | Short, close to the physiological pattern | Medium (without DAC) or prolonged (with DAC) |
| Basis of the difference | Base molecule, sensitive to DPP-4 | DPP-4-resistant substitutions (± albumin binding) |
| Pulsatilidad | Better respects the physiological pulse | Less pulsatile, more sustained |
Both act on the GHRH receptor. Sermorelin corresponds to the active fragment GHRH(1-29): it is short-acting and better respects the physiological pulsatility of GH. CJC-1295 adds substitutions that make it resistant to DPP-4 (and, in its DAC version, albumin binding), which markedly prolongs its duration.
The trade-off is clear: longer duration simplifies administration but moves away from the pulsatile pattern; shorter action respects it better at the cost of greater frequency. It is a direct example of how small sequence modifications yield large pharmacokinetic changes.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
Yes. Both are GHRH analogs and act on the GHRH receptor. The difference lies in the pharmacokinetics, not the pathway.
CJC-1295, thanks to DPP-4-resistant substitutions and, in its DAC version, albumin binding. Sermorelin is short-acting and closer to the physiological pattern.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →